The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.
News|Articles|September 10, 2026
- Contagion, Summer 2026 Digital Edition
- Volume 11
- Issue 2
This Is the “Weight” Forward: GLP-1 Use in HIV Care
Fact checked by: Nicole Canfora Lupo
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
Advertisement
Advertisement
People living with HIV (PLWH) face a myriad of risks for comorbidities, including metabolic complications, that extend goal therapeutic outcomes well beyond just maintaining viral suppression. The intersection of HIV infection, antiretroviral therapy (ART), and metabolic disease has created unique clinical challenges that demand preemptive innovative therapeutic approaches.1 Among emerging treatment options, glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists have garnered increasing attention for their potential to address multiple metabolic complications. Although GLP-1 agonists, such as semaglutide, liraglutide, and tirzepatide (a dual GLP-1/GIP agonist), are FDA approved for several metabolic-related indications beyond adjunct diabetes mellitus treatment, such as reducing the risk of major adverse cardiovascular events and reducing further renal dysfunction for type 2 diabetes and obesity in the general population, their use in PLWH remains a promising yet evolving area of study.2,3
Related to this article
Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
The company, Family Farmstead Dairy, issued a raw cheddar recall over potential contamination with Shiga toxin-producing Escherichia coli (STEC) is happening across 7 states.
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
As of October 15, CDC reports 9235 confirmed cases and 4444 deaths in the Bundibugyo virus Ebola outbreak in the DRC, now the second-largest on record.
Advertisement
Advertisement